SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,051,534 | +184.3% | 391,231 | +357.2% | 0.05% | +152.6% |
Q1 2022 | $2,832,000 | -69.6% | 85,572 | -60.9% | 0.02% | -69.4% |
Q4 2021 | $9,318,000 | +322.0% | 219,051 | +339.5% | 0.06% | +313.3% |
Q3 2021 | $2,208,000 | +135.6% | 49,841 | +298.1% | 0.02% | +114.3% |
Q1 2021 | $937,000 | -95.4% | 12,520 | -94.7% | 0.01% | -96.1% |
Q4 2020 | $20,325,000 | +28.5% | 234,939 | -9.2% | 0.18% | +8.5% |
Q3 2020 | $15,819,000 | +48.5% | 258,819 | +1.0% | 0.16% | +42.6% |
Q2 2020 | $10,656,000 | +697.6% | 256,275 | +450.9% | 0.12% | +576.5% |
Q1 2020 | $1,336,000 | +239.1% | 46,516 | +752.9% | 0.02% | +325.0% |
Q4 2019 | $394,000 | +13.9% | 5,454 | +153.7% | 0.00% | -33.3% |
Q1 2018 | $346,000 | -68.1% | 2,150 | -90.9% | 0.01% | -68.4% |
Q3 2016 | $1,085,000 | -38.6% | 23,560 | -59.8% | 0.02% | -48.6% |
Q2 2016 | $1,768,000 | -9.2% | 58,670 | -3.4% | 0.04% | -9.8% |
Q1 2016 | $1,947,000 | – | 60,720 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |